| 标题 |
 The Effect of Empagliflozin on Fluid Volume Status and Cardiac Adipose Tissue in Patients at Risk of Heart Failure: main Results from the Empire Prevent Metabolic Trial 相关领域
恩帕吉菲
医学
脂肪组织
心力衰竭
心脏病学
内科学
血管内容积状态
糖尿病
血流动力学
内分泌学
2型糖尿病
|
| 网址 | |
| DOI | |
| 其它 |
Abstract： Background: Sodium glucose co‐transporter 2 (SGLT2) inhibitors have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes, heart failure (HF) or chronic kidney disease (CKD), namely by reducing HF hospitalizations. Hypervolaemia and excessive epicardial adipose tissue (EAT) contribute to HF pathophysiology and are both prevalent in obesity. However, the effect of SGLT2 inhibitors in patients with obesity without diabetes and HF remains unknown. |
| 求助人 | |
| 下载 | |
|
温馨提示：该文献已被科研通 学术中心 收录，前往查看
科研通『学术中心』是文献索引库，收集文献的基本信息（如标题、摘要、期刊、作者、被引量等），不提供下载功能。如需下载文献全文，请通过文献求助获取。
|
PDF的下载单位、IP信息已删除
浮游
eric888
小青椒
LaTeXer
Dean
Koalas
昏睡的蟠桃
不配.
唐泽雪穗
8R60d8
lilili
Xiaoxiao
子车茗
ephore
changping
无极微光
Tourist
Criminology34
tuanheqi
遇上就这样吧
金金
pcr163
老阎
xzy998
jenningseastera
GPTea
风清扬
Bio
皖公网安备34019202002308
